We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+39.69%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.16B
AUM Growth
+$655M
Cap. Flow
-$8.33M
Cap. Flow %
-0.26%
Top 10 Hldgs %
29.57%
Holding
149
New
12
Increased
35
Reduced
32
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$68M
2
HUM icon
Humana
HUM
+$58.7M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$21.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$21M
5
APRE icon
Aprea Therapeutics
APRE
+$19.9M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$49M
2
ABBV icon
AbbVie
ABBV
+$39.8M
3
SYK icon
Stryker
SYK
+$38.7M
4
MDCO
Medicines Co
MDCO
+$32.8M
5
CI icon
Cigna
CI
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 90.33%
2 Consumer Staples 0.66%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
101
Spyre Therapeutics
SYRE
$9.25B
$6.11M 0.19%
32,000
– –
CHMA
102
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.75M 0.18%
1,160,000
+260,000
+29% +$1.35M
HCAT icon
103
Health Catalyst
HCAT
$128M
$5.55M 0.18%
160,000
+35,000
+28% +$1.16M
TXG icon
104
10x Genomics
TXG
$6.61B
$5.53M 0.17%
72,500
+9,000
+14% +$541K
SRGA
105
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$5.34M 0.17%
65,000
– –
SPRO icon
106
Spero Therapeutics
SPRO
$73M
$5.05M 0.16%
525,000
– –
AKRO
107
DELISTED
Akero Therapeutics
AKRO
$4.99M 0.16%
225,000
– –
CO
108
DELISTED
Global Cord Blood Corporation
CO
$4.63M 0.15%
925,000
– –
GMDA
109
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$4.3M 0.14%
1,000,000
– –
BLUE
110
DELISTED
bluebird bio
BLUE
$3.07M 0.1%
2,702
-926
-26% -$1.01M
ACRS icon
111
Aclaris Therapeutics
ACRS
$869M
$3.02M 0.1%
1,600,000
-1,374,754
-46% -$2.28M
OBSV
112
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.02M 0.1%
789,480
-570,520
-42% -$2.97M
NBRV
113
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.77M 0.09%
8,400
-800
-9% -$367K
MGNX icon
114
MacroGenics
MGNX
$257M
$2.5M 0.08%
230,000
-70,000
-23% -$693K
ANAB icon
115
AnaptysBio
ANAB
$1.68B
$2.19M 0.07%
135,000
-105,000
-44% -$2.48M
FPRX
116
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.84M 0.06%
400,000
-375,000
-48% -$1.49M
PRTK
117
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.51M 0.05%
375,000
-75,000
-17% -$260K
ADAP
118
DELISTED
Adaptimmune Therapeutics
ADAP
$960K 0.03%
800,000
-75,000
-9% -$80K
CRVS icon
119
Corvus Pharmaceuticals
CRVS
$1.17B
$816K 0.03%
150,000
-250,000
-63% -$874K
BMY.RT
120
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$557K 0.02%
+185,150
New +$481K
APLT
121
DELISTED
Applied Therapeutics
APLT
$554K 0.02%
+20,315
New +$348K
PFE icon
122
Pfizer
PFE
$153B
$407K 0.01%
+10,962
New +$390K
CVET
123
DELISTED
Covetrus, Inc. Common Stock
CVET
$273K 0.01%
20,683
– –
ABBV icon
124
AbbVie
ABBV
$435B
– –
-525,000
Closed -$39.8M
ABT icon
125
Abbott
ABT
$187B
– –
-122,500
Closed -$10.3M
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rock Springs Capital Management held 149 positions worth $3.16B, up 26% from $2.51B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2019 filing shows 12 new, 35 increased, 32 reduced and 19 closed positions. Its largest new stake was Humana: 185,000 shares worth $67.8M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2019 buy was Humana: 185,000 shares worth $67.8M.
  • Rock Springs Capital Management added most to Johnson & Johnson in Q4 2019, an estimated $68M increase.
  • Rock Springs Capital Management's biggest Q4 2019 reduction was Medicines Co, cutting an estimated $32.8M.
  • Rock Springs Capital Management fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $3.16B portfolio in Q4 2019.
  • Rock Springs Capital Management opened 12 new positions and closed 19 in Q4 2019.
  • Rock Springs Capital Management's portfolio value rose 26% quarter-over-quarter to $3.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.